Scarica l'app Stockscreener
12.10
3.15%
0.37
Dopo l'orario di chiusura:
12.10
Alvotech Borsa (ALVO) Ultime notizie
Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023) - Yahoo Finance
Earnings call: Alvotech reported revenues of $128 million - Investing.com India
Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements - Investing.com Canada
Alvotech Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call: Alvotech reported revenues of $128 million By Investing.com - Investing.com Canada
Alvotech earnings missed, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Alvotech earnings missed, revenue fell short of estimates - Investing.com India
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges By Investing.com - Investing.com Australia
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates - MSN
Alvotech : First 9 Months Earnings and Business Update 2024 - Marketscreener.com
Alvotech Showcases Strong Financial Growth and Expansion - TipRanks
Alvotech Reports Financial Results for the First Nine Months of 2024 - The Manila Times
Alvotech Revenue Soars 800% to $339M, Achieves First Positive EBITDA | ALVO Stock News - StockTitan
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges - Investing.com
EMA Accepts Marketing Authorization Application for Alvotech’s AVT05 (golimumab) - JD Supra
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - The Manila Times
Alvotech Attending Citi's Global Healthcare Conference on - GlobeNewswire
Alvotech to Present at Citi and Evercore Healthcare Conferences in December | ALVO Stock News - StockTitan
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024 - Yahoo Finance
ADVANZ PHARMAEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi - Marketscreener.com
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi - BioPharma-Reporter.com
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for its biosimilar of J&J’s Simponi - BioPharma-Reporter.com
EMA accepts Alvotech and Advanz Pharma’s AVT05 MAA - Pharmaceutical Technology
Alvotech application for Simponi biosimilar accepted by EMA - MSN
Alvotech’s AVT05 Biosimilar Application Accepted by EMA - TipRanks
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - The Manila Times
European Medicines Agency Confirms Acceptance of Marketing - GlobeNewswire
Alvotech Petitions FDA To Deny Interchangeability For Rival Stelara Biosimilars - Citeline
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - The Manila Times
Alvotech to Report Financial Results for the First Nine - GlobeNewswire
Alvotech, Teva obtain FDA nod for new Selarsdi indication - Drug Store News
Exploring High Growth Tech Stocks In The US October 2024 - Simply Wall St
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - StockTitan
Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire
FDA approves Alvotech and Teva’s SELARSDI for new indications - MSN
Alvotech's SWOT analysis: biosimilar powerhouse stock faces growth hurdles - Investing.com
Teva, Alvotech get expanded FDA approval for Stelara biosimilar - MSN
Teva, Alvotech get expanded FDA approval for Stelara biosimilar (NYSE:TEVA) - Seeking Alpha
Alvotech and Teva Secure FDA Approval for SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - The Manila Times
Teva, Alvotech announce U.S. FDA approval of presentation of SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional - GlobeNewswire
Alvotech (NASDAQ:ALVO) Short Interest Update - MarketBeat
Generics Bulletin | Insights on Off-Patent and Generic Medicines | Insights - Citeline
Alvotech Advances With EU Application Acceptance - TipRanks
Alvotech application for Prolia/Xgeva biosimilar accepted by EMA (NASDAQ:ALVO) - Seeking Alpha
ALVOAlvotech Ordinary Shares Latest Stock News & Market Updates - StockTitan
0.79%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):